• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pulse Biosciences Inc

    2/27/25 5:17:29 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email
    S-8 1 plse20240920_s8.htm FORM S-8 plse20240920_s8.htm

     

    Registration No. 333-

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

         

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

         

     

    Pulse Biosciences, Inc.

    (Exact name of Registrant as specified in its charter)

     

         

     

    Delaware

     

    46-5696597

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

    

    601 Brickell Key Drive, Suite 1080

    Miami, FL 33131

     

    

    (Address of Principal Executive Offices) (Zip Code)

     

     

    2017 Inducement Equity Incentive Plan

    (Full title of the plan)

     

         

     

    

    Paul A. LaViolette

    Chief Executive Officer

    Pulse Biosciences, Inc.

    601 Brickell Key Drive, Suite 1080

    Miami, FL 33131

     
     

    (Name and address of agent for service)

     

     

         

     

    

    (510) 906-4600

     
     

    (Telephone number, including area code, of agent for service)

     

     

         
     

    Copies to:

     

    

    Kenneth B. Stratton, Esq.

    General Counsel

    Pulse Biosciences, Inc.

    601 Brickell Key Drive, Suite 1080

    Miami, FL 33131

    (510) 906-4600

    Adam W. Finerman

    Baker & Hostetler LLP

    45 Rockefeller Center

    New York, NY 10111

    (212) 589-4233

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒ 

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 2,000,000 additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) under the Company’s 2017 Inducement Equity Incentive Plan. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on November 28, 2017 (File No. 333-221788) and June 10, 2021 (File No. 333-256992).

     

    PART I

     

    INFORMATION REQUIRED IN THE PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants of the Incentive Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    Pulse Biosciences, Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission, in each case excluding any information “furnished” but not “filed,” unless the Company specifically provides that such “furnished” information is to be incorporated by reference:

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on March 28, 2024 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

     

    (b)

    The Registrant’s Quarterly Reports on Form 10-Q for its fiscal quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, filed with the Commission on May 7, 2024, August 19, 2024 and October 30, 2024, respectively, pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

     

    (c)

       The Registrant’s Current Reports on Form 8-K filed with the Commission pursuant to the Exchange Act on each of January 2, 2024, February 14, 2024, March 11, 2024, March 28, 2024, May 2, 2024, May 9, 2024, May 15, 2024, May 20, 2024, June 7, 2024, June 28, 2024, July 3, 2024, July 8, 2024, July 15, 2024, August 8, 2024, August 12, 2024, October 30, 2024, October 31, 2024, December 6, 2024, December 26, 2024, January 13, 2025, January 23, 2025 and February 4, 2025, respectively;

     

     

    (d)

    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

     

     

    (e)

       The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-37744) filed with the Commission on April 15, 2016, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

     

     

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable. 

     

    Item 6. Indemnification of Directors and Officers.

     

    Under Section 145 of the Delaware General Corporation Law, Registrant has broad powers to indemnify its directors and officers against liabilities they may incur in such capacities, including liabilities under the Securities Act. Registrant’s Bylaws (the “Bylaws”) provide that Registrant shall indemnify its directors and officers if such officer or director acted (i) in good faith, (ii) in a manner reasonably believed to be in or not opposed to the best interests of Registrant, and (iii) with respect to any criminal action or proceeding, had no reasonable cause to believe such conduct was unlawful. Registrant believes that indemnification under its Bylaws covers at least negligence and gross negligence, and requires Registrant to advance litigation expenses in the case of stockholder derivative actions or other actions, against an undertaking by the directors and officers to repay such advances if it is ultimately determined that the director is not entitled to indemnification. The Bylaws further provide that rights conferred under such Bylaws shall not be deemed to be exclusive of any other right such persons may have or acquire under any agreement, vote of stockholders or disinterested directors, or otherwise.

     

    In addition, Registrant’s Certificate of Incorporation (the “Certificate of Incorporation”) provides that, pursuant to Delaware law, none of its directors shall be liable for monetary damages for breach of his or her fiduciary duty of care to Registrant and its stockholders to the fullest extent permitted by the Delaware General Corporation Law as it presently exists or may hereafter be amended from time to time. This provision in the Certificate of Incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director’s duty of loyalty to Registrant for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are in willful or negligent violation of applicable Delaware law. The provision also does not affect a director’s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. The Certificate of Incorporation further provides that Registrant shall indemnify its directors and officers to the fullest extent permitted by law and requires Registrant to advance litigation expenses in the case of stockholder derivative actions or other actions, against an undertaking by the director to repay such advances if it is ultimately determined that the director is not entitled to indemnification. The Certificate of Incorporation also provides that rights conferred under such Certificate of Incorporation shall not be deemed to be exclusive of any other right such persons may have or acquire under any statute, the Certificate of Incorporation, the Bylaws, agreement, vote of stockholders or disinterested directors, or otherwise.

     

    Registrant has obtained liability insurance policies for the officers and directors that, subject to certain limitations, terms and conditions, will insure them against losses arising from wrongful acts (as defined by the policy) in their capacity as directors or officers.

     

    In addition, Registrant has entered into agreements to indemnify its directors and certain of its officers in addition to the indemnification provided for in the Certificate of Incorporation and Bylaws. These agreements, among other things, indemnify Registrant’s directors and certain of its officers for certain expenses (including attorney’s fees), judgments, fines and settlement amounts incurred by such person in any action or proceeding, including any action by or in the right of Registrant, on account of services as a director or officer of Registrant or as a director or officer of any subsidiary of Registrant, or as a director or officer of any other company or enterprise that the person provides services to at the request of Registrant.

     

    See also the undertakings set out in response to Item 9 herein.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable. 

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement.

     

    

    Incorporated by Reference

    Exhibit Number

    Description

    Form

    File No.

    Exhibit

    Filing Date

    4.1 Certificate of Incorporation of the Registrant 8-K12B 001-37744 3.3 June 18, 2018
    4.2 Bylaws of the Registrant 8-K12B 001-37744 3.4 June 18, 2018

    4.3

    Form of Common Stock certificate of the Registrant

    8-K12B

    001-37744

    4.1

    June 18, 2018

    4.4*

    Pulse Biosciences, Inc. 2017 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder.

     

     

     

     

    5.1*

    Opinion of Baker & Hostetler LLP, counsel to the Registrant

           

    23.1*

    Consent of Independent Registered Public Accounting Firm

           

    23.2*

    Consent of BakerHostetler LLP (included in Exhibit 5.1)

           

    24.1*

    Power of Attorney (contained on signature pages hereto)

           

    107*

    Filing Fee Table

           

     

    * Filed herewith.

     

     

     

     

    Item 9. Undertakings.

     

    A.         The undersigned Registrant hereby undertakes:

     

    (1)        To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)         To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)        To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii)       To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

     Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2)        That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)         To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    B.          The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    C.          Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, Florida, on February 27, 2025.

     

    

    PULSE BIOSCIENCES, INC.

    

       

    

    By:

    /s/ Paul A. LaViolette

    

      Paul A. LaViolette

    

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Paul A. LaViolette and Kenneth B. Stratton, and each of them singly, as the undersigned’s true and lawful attorney-in-fact and agent with full power of substitution, for the undersigned in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or the undersigned’s substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

    /s/ Paul A. LaViolette  

    Chief Executive Officer

     

    February 27, 2025

    Paul A. LaViolette  

    (Principal Executive Officer)

       

    

           
    /s/ Jon Skinner   Chief Financial Officer   February 27, 2025
    Jon Skinner   (Principal Financial Officer)    
             

    /s/ Robert W. Duggan

     

    Co-Chairman of the Board of Directors

      February 27, 2025

    Robert W. Duggan

           

    

           

    /s/ Darrin R. Uecker

     

    Chief Technology Officer and Director

      February 27, 2025

    Darrin R. Uecker

           

    

           

    /s/ Manmeet S. Soni

     

    Director

      February 27, 2025

    Manmeet S. Soni

           
             

    /s/ Richard A. van den Broek

     

    Director

      February 27, 2025

    Richard A. van den Broek

           
             

    /s/ Mahkam Zanganeh

     

    Director

      February 27, 2025

    Mahkam Zanganeh

           
             

    /s/ Timothy H. Mitsuoka

     

    Corporate Controller

      February 27, 2025

    Timothy H. Mitsuoka

     

    (Principal Accounting Officer)

       

     

     
    Get the next $PLSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

      2/10/22 6:14:40 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

      11/16/21 9:11:22 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Stephens & Co. initiated coverage on Pulse Biosciences with a new price target

      Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00

      7/27/21 5:53:59 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Financials

    Live finance-specific insights

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelect

      4/24/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

      3/27/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

      SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      7/8/24 3:30:25 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/14/23 7:21:15 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/4/23 5:18:06 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

      Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

      2/4/25 8:00:00 AM ET
      $AXTA
      $PLSE
      $TFX
      Paints/Coatings
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

      Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

      10/30/24 4:02:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

      Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

      8/12/24 4:01:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. Pulse Biosciences' Management is scheduled to present on Wednesday, May 14, 2025, at 5:00 pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as we

      5/6/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on April 21, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 19,500 shares of Company common stock. The Company's independent

      4/25/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zanganeh Mahkam exercised 60,242 in-the-money shares at a strike of $11.00, increasing direct ownership by 9% to 725,395 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      2/11/25 6:20:57 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Laviolette Paul A

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      1/13/25 7:45:33 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Barrett Burke Thomas sold $871,000 worth of shares (50,000 units at $17.42), decreasing direct ownership by 44% to 63,172 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/20/24 5:00:42 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 8:02:46 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 6:05:11 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/13/24 7:30:48 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pulse Biosciences Inc

      10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 5:24:22 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 4:22:58 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Pulse Biosciences Inc

      10-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      4/30/25 9:08:54 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care